Alkermes (ALKS)

Executive Summary

Alkermes plc is a fully integrated biopharmaceutical company specializing in innovative therapies for psychiatric and neurological disorders. With a strong commercial portfolio including Lybalvi (olanzapine/samidorphan) for schizophrenia and bipolar I disorder, and Vivitrol (naltrexone extended-release) for alcohol and opioid dependence, the company generates meaningful revenue and maintains a robust pipeline. Alkermes leverages its deep neuroscience expertise and proprietary formulation technologies to address unmet needs in addiction, serious mental illness, and sleep disorders. The company's late-stage pipeline features ALKS 2680, a novel orexin 2 receptor agonist for narcolepsy type 1, which recently completed a Phase 2 study with promising results, and OLZ/SAM, a combination therapy in Phase 3 for bipolar I disorder. These programs, along with a disciplined R&D strategy, position Alkermes for sustained growth and continued leadership in CNS therapeutics. Alkermes' near-term outlook is supported by its commercial execution and upcoming pipeline milestones. The company is expected to initiate Phase 3 trials for ALKS 2680 in narcolepsy following positive Phase 2 data, while the OLZ/SAM Phase 3 study for bipolar I disorder continues to enroll. Additionally, Alkermes may explore label expansions for existing products or pursue strategic partnerships to maximize the value of its pipeline. With a proven track record of bringing CNS drugs to market and a strong balance sheet, Alkermes offers a balanced risk-reward profile for investors seeking exposure to neuroscience innovation. However, competition in the CNS space and regulatory uncertainties remain key risks.

Upcoming Catalysts (preview)

• Q3 2026ALKS 2680 Phase 2 topline data presentation and Phase 3 start65% success
• H2 2026OLZ/SAM Phase 3 enrollment completion for bipolar I disorder80% success
• TBDPotential label expansion or new partnership for Lybalvi or Vivitrol50% success